|
Name: Solriamfetol (2-amino-3-phenylpropyl car-bamate; benzenepropanol, beta-amino-, carbamate (ester))
Type: Stimulant
AKA: N/A
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Solriamfetol (solriamfetol, beta amino, carbamate (ester); benzenepropanol, beta amino, carbamate (ester)) was discovered in the late 1950's by Dr. William G. McGonigle, then a postdoctoral fellow at the University of Rochester. McGonigle was working on a project that involved the synthesis of amino acids. He was asked to test a number of synthetic amino acids in order to determine which ones might have the potential to be used as drugs. One of the amino acids that he tested was solriamfetol (beta amino, carbamate (ester)).
McGonigle had previously synthesized another amino acid, but it had not been used as a drug. McGonigle tested solriamfetol to determine if it might be useful as a drug.
Solriamfetol is a derivative of the amino acid beta-alanine (beta-alanyl,
|
|
V. Legal Information
Solriamfetol is a medication used to treat excessive daytime sleepiness. It is controlled to manage its medical use and prevent misuse. [Source: UNODC].
US Federal Schedule - IV
Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Solriamfetol is a wakefulness-promoting agent used to treat sleep disorders. It causes increased alertness, elevated heart rate, and dilated pupils. Short-term use improves wakefulness, while long-term use may lead to cardiovascular issues and dependence. Overdose risks include severe agitation and cardiovascular problems. Safe use involves adherence to prescribed doses. Recent research highlights its effectiveness for sleep disorders and associated cardiovascular risks.  |
|
VII. Psychological Effects
Solriamfetol, a stimulant, affects dopamine and norepinephrine systems, leading to increased alertness and mood enhancement. Immediate effects include improved mood and energy, lasting several hours. Long-term use may result in cognitive impairments and mood disturbances. Research emphasizes its efficacy as a wakefulness-promoting agent and associated risks of psychological dependence and cognitive effects.
 |
|
VIII. Culture
Solriamfetol is a stimulant medication used for the treatment of excessive daytime sleepiness. Its cultural significance relates to its role in managing sleep disorders, particularly narcolepsy and obstructive sleep apnea. Media coverage often focuses on the effectiveness of such medications in improving quality of life and managing symptoms. Solriamfetol is used medicinally and is part of broader discussions about sleep disorders, treatment options, and the management of daytime sleepiness.
 |